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Abstract
Background: The aim of this work is to refine understanding of anatomical and functional alterations in eyes with
Intermediate Uveitis (IU), their natural history in mild cases not necessitating treatment and their response to treatment
in severely affected eyes with macular edema.
Methods: 61 consecutive patients with IU presenting over a 6-year period were prospectively recruited into the
study. Two subgroups of patients with IU were identified on the basis of the need or not for systemic cortico-steroid
treatment. A group of healthy volunteers was identified for determining normal average central foveal thickness (CFT)
values. Statistical comparisons were sought between patient sub-groups and with the group of normal volunteers for
CFT and Best Corrected Visual Acuity (BCVA) at baseline and after 6 months. In a post hoc analysis, a cut-off value of
CFT for systemic treatment initiation in IU was statistically identified and its sensitivity and specificity determined.
Results: A statistically significant difference in mean CFT at baseline was observed between patients under systemic
treatment and untreated patients (p = 0.0005) as well as between untreated patients and healthy volunteers. (p < 0.001)
After six months difference in CFT between the two patients subgroups was no longer significant (p = 0.699). BCVA was
worse for patients under systemic treatment. No statistically significant difference could be identified between the
subgroup of untreated patients and the group of healthy volunteers either at baseline or after 6 months. Correlation
between LogMAR visual acuity and central retinal thickness at baseline was strong (r = 0.7436, p < 0.0001, Pearson’s
correlation coefficient). The cut-off value of CFT for initiating systemic treatment was determined at 215.5 μm in a post
hoc analysis (sensitivity 62.5 %, specificity 96.4 %).
Conclusions: Subclinical retinal thickening of mildly inflamed eyes with IU can occur though bearing no functional
clinical significance and spontaneously resolving within 6 months. A cut-off CFT value for treatment of macular edema
in IU, in the presence of other relevant morphological features on Optical Coherence Tomography, seems to emerge
from post hoc analysis of collected data demonstrating strong specificity and moderate sensitivity.
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Background
Intermediate uveitis (IU) is a form of chronic ocular in-
flammation in which the vitreous is the ocular tissue pre-
dominantly affected, according to the SUN classification
[1]. It usually involves a younger age range and comprises
around 10 % of all causes of uveitis. Although unanswered
questions persist concerning its etiology, the condition is
occasionally associated with certain systemic pathologies,
such as sarcoidosis, Lyme disease, Cat-scratch disease and
multiple sclerosis [2]. The term pars planitis is used to
describe the idiopathic form of IU characterized by the
presence of snow-banking and/or snowballs in the vitreous
[1]. Common manifestations of IU include retinal vasculitis,
mainly involving venous branches and the development of
cystoid macular edema (CME). The latter constitutes the
principal factor leading to permanent visual loss in the con-
text of IU and its frequency ranges between 30 and 60 % in
several studies [2–4]. Despite the high incidence of CME,
visual prognosis in IU is favorable with 75 % of patients
retaining a visual acuity of 20/40 or better after ten years
[3]. Poor visual prognosis is mainly associated with the
development of CME, hence the importance of its early
detection and treatment. A plethora of reports have under-
pinned the dominant role of Optical Coherence Tomog-
raphy (OCT) for the diagnosis of macular edema in the
context of ocular inflammation, including IU, and have
identified quantitative and qualitative predictors for visual
outcome [5–9] and response to treatment [10–12]. In the
present prospective study we attempt to refine understand-
ing of the natural history of CME in mild cases of IU not
requiring systemic treatment as well as the response to
treatment of more severe vision-threatening cases. We
emphasize particularly the natural history and clinical sig-
nificance of subclinical macular thickening not previously
described in the context of this condition and we attempt
to identify a threshold as regards CFT on OCT for initiating
systemic cortico-steroid treatment.
Methods
We conducted a prospective study on patients presenting
to the Jules - Gonin Eye Hospital with IU, diagnosed on the
basis of clinical criteria proposed by the SUN classification
[1]. Inclusion criteria also involved willingness of the patient
to offer informed consent and age range between 9 and
77 years. Exclusion criteria were media opacities interfering
with reliable OCT measurements and the presence of any
other ocular condition associated with CME. All research
work adhered to the tenets of the declaration of Helsinki.
All patients underwent a full clinical examination, including
best-corrected visual acuity (BCVA), tonometry and dilated
fundus examination by indirect ophthalmoscopy with pars
plana indentation. The following laboratory tests were per-
formed on all patients: complete blood count, erythrocyte
sedimentation rate, serum lysozyme, angiotensin converting
enzyme, calcium and serologies for syphilis, Lyme disease,
Cat-scratch disease. A quantiferon test or a tuberculin skin
test to rule out tuberculosis and a chest X-ray were also
performed. Fluorescein angiography was performed in all
patients presenting with a visual acuity of 0.8 or worse or
manifesting clinical signs of vasculitis, severe vitritis or
macular edema. The decision to introduce a systemic treat-
ment was based on clinical, OCT and/or angiographic cri-
teria. More precisely, systemic cortico-steroid therapy was
introduced in the presence of a loss of visual acuity of one
or more lines (each line on the standardized visual acuity
chart increasing by 0.1 log units), macular edema detected
clinically or on OCT (including any presence of intraretinal
cysts, irrespective or central retinal thickness), signs of
moderate to severe vasculitis on clinical examination or
angiography, more than 2+ of vitreous cells or more than 1
+ of vitreous haze (assessed clinically on the basis of the
SUN) classification, peripheral serous retinal detachment or
papillitis. Systemic corticosteroids were used as first line
therapy. Posterior subtenon’s steroid injections were used
as second line therapy in view of the commonly bilateral
nature of IU and the potential steroid responsiveness to
subtenon’s injections. Steroid sparing agents were intro-
duced in a second line therapy, when corticosteroids could
not be tapered off after more than 3 months according to
international guidelines. None of the patients were on
immunosuppressive therapy during their inclusion in the
study. A Stratus OCT was used (Zeiss Humphrey Systems,
San Leandro, CA) with a cross-sectional scan performed at
the macula to measure CFT (Fig. 1). In the presence of
bilateral ocular inflammation, only the more severely in-
flamed eye was considered as the study eye, so as to ac-
count for inter-eye correlation in cases of bilateral
involvement. The same evaluations as the ones performed
at baseline were repeated 5 ± 1.6 months after initial evalu-
ation. A group of 27 age-matched healthy volunteers with-
out any ocular disease was included in the study. 6–10
OCT measurements per eye of the healthy volunteers were
performed and averaged to determine normal values of
central foveal thickness. For the purposes of refining under-
standing of disease behaviour, two sub-groups of patients
were considered on the basis of the need or not of systemic
treatment for IU. The first sub-group consisted of patients
to whom systemic corticosteroids were administered and
the second of patients without treatment, other than a
short course of topical corticosteroids. This consisted of a
course of prednisolone 1 % drops QDS on a tapering regi-
men over a period of 4–6 weeks. The amount of topical
steroids did not vary between the two patient groups.
Statistical significance of difference in mean CFT between
the two patient sub-groups, as well as between each patient
sub-group and the group of healthy volunteers was
assessed at baseline and at the end of follow-up. The same
statistical analysis was performed for difference in mean
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BCVA between the various groups at baseline and at the
end of follow-up. The correlation between visual acuity
and central foveal thickness at baseline was also evaluated.
For purposes of statistical analysis Snellen visual acuity
values were converted to the LogMAR scale. A post hoc
analysis was performed in order to identify a cut-off value
of CFT for initiating systemic cortico-steroid treatment.
The sensitivity and specificity of this cut-off value were
evaluated against the actual presence or absence of severe
disease warranting systemic treatment in this patient co-
hort. Mann-Whitney-Wilcoxon test for independent sam-
ples (MWW), Wilcoxon matched pairs test and Pearson’s
correlation coefficient were appropriately applied. Level of
statistical significance was set to 5 %. Statistical analysis
was performed with the use of the JMP software (JMP
8.0.1 copyright 2009 SAS institutes (www.jmp.com)).
Results
The study sample consisted of 61 consecutive patients, of
which 31 males and 30 females with a mean age of 30 ±
17 years, prospectively followed for a period of 6 months.
There were 57 patients with pars planitis, 2 were diagnosed
with sarcoidosis and 2 with Lyme disease. 29 patients did
not receive systemic treatment, while 32 patients received
systemic cortico-steroid treatment with an initial dosage of
1 mg/kg/day. A progressive tapering regimen was used with
a decrease of 5 mg every three to four weeks. The control
group of 27 healthy subjects consisted of 12 men and 15
women with a mean age of 36 ± 16 years ((p = 0.139)
for mean age difference between patient and control
group, t-test). All patients were phakic. CFT was 176
± 16 μm for the normal volunteers (n = 27), while it
was 310 ± 182 μm for the group of patients under sys-
temic treatment (n = 32) and 183 ± 24 μm for the group of
untreated patients (n = 29). Difference in CFT at baseline
was statistically significant between normal subjects and
untreated patients (p < 0.0001, MWW), normal subjects
and patients under systemic treatment (p < 0.0001, MWW)
and between treated and untreated patients (p = 0.0005,
MWW) [Table 1].
15 patients did not complete the full 6 months follow-up
period (8 patients in the group of untreated patients and 7
patients in the group of systemically treated patients). For
patients available for the 6-months follow-up visit (mean
CFT of 325 ± 122 at baseline) mean CFT decreased in a
statistically significant manner to 209 ± 86 μm for the group
of treated patients (n = 25, p = 0.0004, Wilcoxon matched
Fig. 1 OCT Measurement of central foveal thickness. A cross sectional scan was performed at the macula (white double arrow). Central foveal thickness
was determined by automated segmentation of retinal layers and positioning of the marker at the apex of the curve in the thickness chart. Central foveal
thickness of 249 microns was measured in this case
Table 1 Statistical significance of difference in central retinal
thickness between the various groups
Untreated
patients
Treated patients Control
group
Untreated patients Baseline
p = 0.0005
6 months
p = 0.699
Baseline
p < 0.0001
Treated patients Baseline
p < 0.0001
Control group
p-values derived from Mann-Whitney-Wilcoxon test
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pairs), while it remained practically unchanged in the group
of untreated patients (181 ± 29 μm from 179 ± 18 at base-
line) (n = 21, p = 0.561, Wilcoxon matched pairs). Differ-
ence in CFT was no longer statistically significant between
the two patient subgroups (p = 0.699, MMW).
Mean initial BCVA differed in a statistically significant
manner between the two patient sub-groups (p < 0.0001,
MWW), but not between untreated patients and the
group of normal volunteers (p = 0.085, MWW) [Table 2].
Mean BCVA slightly, though statistically significantly, im-
proved in the group of treated patients, passing from
0.222 ± 0.249 to 0.087 ± 0.125 (p = 0.0075, Wilcoxon
matched pairs), while it remained practically unchanged
in the group of untreated patients, passing from 0.024 ±
0.085 to 0.015 ± 0.060 (p = 0.644, Wilcoxon matched
pairs). Changes in CFT and BCVA for the two patient
subgroups over the follow-up period are summarized in
Table 3. Difference in BCVA between the two patient sub-
groups remained statistically significant at the end of fol-
low-up (p = 0.032, MWW). There was a strong
correlation between baseline BCVA and CFT on OCT
(r = 0.743, p < 0.0001 Pearson’s correlation coefficient).
Comparisons bear on patients that completed the
6 months of follow up only. In the post hoc analysis a
CFT cut-off for initiating treatment with systemic
cortico-steroids was determined at 215.5 μm in the
present cohort. The sensitivity of this value was moder-
ate at 62.5 %, yet its specificity was strong at 96.4 %.
Discussion
The present study accrues useful additional clues in our
understanding of the anatomical and functional repercus-
sions of IU and its response to cortico-steroid treatment.
Segregating patients with respect to the need for systemic
treatment for CME and comparing anatomical and func-
tional outcomes between patient sub-groups and with a
group of healthy volunteers in a prospective study design
allowed identifying the presence of subclinical retinal thick-
ening in milder, not systemically treated cases as well as the
clinical significance of this phenomenon. Re-affirming the
established favorable prognosis to systemic treatment of
CME secondary to IU, there was a statistically significant
decrease in CFT after a period of 6 months in the sub-
group of more severely affected patients, which translated
into a significant, though slight, improvement in BCVA.
Although in the group of patients that did not receive
systemic treatment mean CFT was significantly inferior to
that of the treated group, it was, nevertheless, significantly
superior to that of the group of healthy volunteers. Despite
this marginal retinal thickening in the group of untreated
patients, retinal thickness did not increase further in the
course of follow-up, nor was there a significant drop in vis-
ual acuity suggesting no clinical significance of subclinical
retinal thickening in milder cases of IU. This slight, though
statistically significant, macular thickening in the group of
patients with mild disease, not necessitating systemic
treatment, is a striking finding not previously identified in
the context of IU. This patient sub-group presented sub-
clinical macular thickening, as evidenced by the absence
of visual acuity loss in these patients, compared to the
group of normal volunteers. Few studies have tackled the
issue of subclinical retinal thickening in other forms of
intraocular inflammation, such as acute anterior uveitis
(AAU) [13, 14]. These include a retrospective study by
Castellano [13], demonstrating a statistically significant
difference in retinal thickness between the study and
fellow eye for all OCT subfields in patients with acute
anterior uveitis and the prospective study by Balaskas et
al. [15] that offered a model of quantification of retinal
thickness asymmetry between fellow eyes in the course of
an episode of AAU. The identification of a critical value of
retinal thickness beyond which systemic treatment is
clearly indicated in patients with IU has yet to be deter-
mined, though it would constitute a powerful clinical tool.
Although a precise CFT threshold for treatment cannot be
envisaged in isolation, our post hoc analysis determined a
cut-off value of 215.5 μm for commencing treatment in the
present cohort. Clinical management decisions cannot be
based on CFT values alone, however CFT should be taken
into consideration when reaching management decisions
alongside other qualitative morphological features on OCT,
most importantly the presence of cystoid spaces. In the
presence of cystic changes on OCT, however, determining a
cut-off CFT value beyond which the risk-benefit ratio is
Table 2 Statistical significance of difference in LogMAR BCVA
between the various groups
Untreated
patients
Treated patients Control
group
Untreated patients Baseline
p < 0.0001
6 months
p = 0.032
Baseline
p = 0.085
Treated patients Baseline
p < 0.0001
Control group
p-values derived from Mann-Whitney-Wilcoxon test
Table 3 Statistical significance of change in central retinal thickness
and BCVA between baseline/end of follow-up. (Patients who
completed 6 months of follow-up)
Baseline 6-months p
Untreated patients
Central foveal thickness (μm) 179 ± 18 181 ± 29 0.561
BCVA (LogMAR) 0.024 ± 0.085 0.015 ± 0.060 0.644
Treated patients
Central foveal thickness (μm) 325 ± 122 209 ± 86 0.0004
BCVA (LogMAR) 0.222 ± 0.249 0.087 ± 0.125 0.0075
p-values derived from Wilcoxon matched pairs test
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tipped in favour of systemic treatment is of particular clin-
ical relevance. When analysed against the actual presence
or absence of severe disease requiring systemic treatment
in our series, this cut-off value for CFT exhibited strong
specificity, yet moderate sensitivity. This may indicate that
cases requiring systemic treatment may occasionally be
missed on the basis of this cut-off value if considered in
isolation, while, on the other hand, this value is an accurate
indicator of severe disease warranting systemic treatment
in the vast majority of such cases. Taking into account that
in a real-life scenario, clinical management decisions will be
based on a multitude of factors rather than on CFT alone,
the strong specificity of this cut-off value may offer a useful
tool to clinicians as an additional argument in favour of
systemic treatment in relevant cases that are more likely to
benefit from it. Strong correlation between CFT thickness
and mean logMAR visual acuity at baseline was observed
in the present study. The issue of correlation between ret-
inal thickness and visual acuity remains controversial with
some studies reporting a high [16] negative correlation and
others failing to verify this finding [17]. Several factors may
play a role in the observed discrepancy, such as structural
characteristics of macular edema, chronicity and underlying
pathology. The high specificity of the identified CFT cut-off
value for initiating systemic treatment in this study suggests
that almost all cases deemed of sufficient severity to war-
rant systemic treatment in our practice, on the basis of vari-
ous clinical indicators and not just OCT findings, had a
CFT that exceeded the determined cut-off value. Although
clinical application of this cut-off CFT value needs to be in
conjunction with other clinical and imaging features rather
than in isolation, its high specificity renders it a useful
adjunct in the decision making process for commencing
systemic treatment in IU. From a practical point of view,
CFT values can be obtained on newer generation OCT
technology as well and can be evaluated against the cut-off
value suggested in this work employing conversion algo-
rithms already reported in the literature, hence retaining
their clinical relevance and usefulness [18, 19]. The present
study has certain limitations. Patients with advanced media
opacities preventing clear visualization of the fundus and
interfering with OCT measurements were excluded. The
use of CFT as a marker of retinal thickness, although not
uncommon in the literature, is a rather less frequently used
clinical endpoint for research when compared to the more
familiar central macular thickness (CMT) value. The
choice of CFT in this work as clinical endpoint re-
sides in the researcher’s reliance on this marker for
clinical decision making in the era of the Stratus
OCT. The age-matched group of healthy volunteers
randomly selected may not be representative of the
general population for determining normal CFT
range, although very similar values for CFT in healthy
eyes have been previously reported [20].
Conclusions
Present study contributes two novel concepts in our under-
standing of macular thickening in the context of IU:
1. Subclinical retinal thickening of mildly inflamed eyes
with IU is a previously unreported phenomenon, with
however no functional clinical significance and
spontaneous resolution by 6 months.
2. A cut-off value of CFT for initiating systemic treatment
of 215.5 μm was identified in the present cohort
exhibiting strong specificity and moderate sensitivity.
This may serve as a useful additional clinical tool aiding
clinicians in reaching therapeutic decisions in patients
with IU.
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